Cholangiocarcinoma (CCA) Epidemiology Forecast 2025-2034

Cholangiocarcinoma (CCA) refers to a group of highly diverse malignant tumors originating at various locations along the biliary tree. Its global incidence is on the rise, representing approximately 15% of all primary liver cancers and around 3% of gastrointestinal malignancies.

Cholangiocarcinoma (CCA) Epidemiology Forecast Report Coverage

The “Cholangiocarcinoma (CCA) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of cholangiocarcinoma (CCA). It projects the future incidence and prevalence rates of cholangiocarcinoma (CCA) across various populations. The study covers age, gender, and type as major determinants of the cholangiocarcinoma (CCA)-affected population. The report highlights patterns in the prevalence of cholangiocarcinoma (CCA) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of cholangiocarcinoma (CCA) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Cholangiocarcinoma (CCA) Disease Overview

Cholangiocarcinoma (CCA) is a rare and aggressive cancer that develops in the bile ducts, which carry bile from the liver to the small intestine. It is categorized into intrahepatic, perihilar, and distal, based on its location within the biliary tree. The disease often manifests with vague symptoms such as jaundice, abdominal pain, weight loss, and itching, making early detection difficult. Key risk factors include primary sclerosing cholangitis, liver fluke infections, chronic inflammation of the bile ducts, and specific genetic mutations. Highly heterogeneous in nature, CCA's global incidence is rising, accounting for about 15% of primary liver cancers and 3% of gastrointestinal malignancies.

Cholangiocarcinoma (CCA): Treatment Overview

Treatment for cholangiocarcinoma (CCA) varies based on its location, stage, and the patient’s overall condition. Surgical resection remains the only potentially curative approach, though many patients present with unresectable or advanced disease. For these cases, systemic therapies such as chemotherapy (e.g., gemcitabine and cisplatin) and targeted treatments, including FGFR2 and IDH1 inhibitors, are commonly used. Symptom management through biliary drainage and stenting can improve quality of life. Promising advancements, such as immunotherapy and locoregional therapies, are being explored in clinical trials. A multidisciplinary approach is essential to optimize treatment outcomes.

Epidemiology

The cholangiocarcinoma (CCA) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for Cholangiocarcinoma (CCA) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for cholangiocarcinoma (CCA) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• CCA accounts for approximately 2% of all cancer-related deaths globally each year. Non-invasive diagnostic methods for cholangiocarcinoma (CCA) currently lack sufficient accuracy. The asymptomatic nature of these tumors in their early stages, coupled with their aggressive behavior and resistance to chemotherapy, significantly contribute to high mortality rates.
• Studies reveal that over the past decade, annual mortality rates for intrahepatic cholangiocarcinoma (iCCA) have declined by 2.5% in the United States but increased by 9% in Europe. The male-to-female ratio for CCA ranges from 1:1.2 to 1:1.5. Also, the average age for diagnosis is over 50 years globally.
• Hepatobiliary malignancies contribute to 13% of cancer-related deaths worldwide and 3% in the United States. Cholangiocarcinoma (CCA) represents 15% to 20% of all primary hepatobiliary malignancies.
• Surgery is the only curative option for cholangiocarcinoma (CCA) but is limited to early-stage patients who are otherwise healthy. Most patients, however, are treated with chemotherapy and, more recently, immunotherapy. Due to the late-stage diagnosis in many cases, the prognosis remains poor, with a 5-year survival rate of less than 20%.

Country-wise Cholangiocarcinoma (CCA) Epidemiology

The cholangiocarcinoma (CCA) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of cholangiocarcinoma (CCA) varies between countries owing to the differences in factors such as chronic liver conditions such as primary sclerosing cholangitis (PSC), parasitic infections caused by liver flukes, bile duct stones, diabetes, obesity, alcohol drinking and tobacco smoking. According to the Global Cholangiocarcinoma Alliance, the incidence rates of cholangiocarcinoma vary across different regions. In Western countries, fewer than six cases per 100,000 individuals are reported annually. In contrast, Southeast Asia - particularly Thailand, South Korea, and China - experiences higher incidence rates, exceeding six cases per 100,000 annually. This regional variation may be linked to exposure to specific risk factors, such as the widespread presence of carcinogenic liver flukes in Southeast Asia.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Cholangiocarcinoma (CCA) based on several factors.
• Cholangiocarcinoma (CCA) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of Cholangiocarcinoma (CCA) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of cholangiocarcinoma (CCA) epidemiology in the 8 major markets?
• What will be the total number of patients with cholangiocarcinoma (CCA) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of cholangiocarcinoma (CCA) in the 8 major markets in the historical period?
• Which country will have the highest number of cholangiocarcinoma (CCA) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of cholangiocarcinoma (CCA) during the forecast period of 2025-2034?
• What are the currently available treatments for cholangiocarcinoma (CCA)?
• What are the disease risks, signs, symptoms, and unmet needs of cholangiocarcinoma (CCA)?

This product will be delivered within 3-5 business days.